Pharmafile Logo

JMC Partners LLP

JMC Partners is an established communications consultancy, with a particular expertise in healthcare. We have an excellent record of informing and influencing public policy on behalf of our clients. In a constantly evolving public policy environment, we work together with our clients to help them navigate the political process and convey their message to the people that count in Westminster and beyond. Our dedicated team provides a truly personalised service based on a genuine understanding of our clients’ goals and aspirations. We pride ourselves on the relationships we build and the results we achieve.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Visions4Health

Visions4Health are market access experts and your gateway to local adoption at pace. Leveraging our lived experience, understanding of national and local healthcare systems, and insights generated by our stakeholder…

View Profile

Company Details

Hudson House, 8 Tavistock Street, London, WC2E 7PP, United Kingdom
020 3178 7569

 Latest Content from PMHub 

08 UX: Pushing the right buttons

Unlocking better outcomes in healthcare with UX

UX: Pushing the right buttons

Unlocking better outcomes in healthcare with UX

07 Good Pharma

Better for patients, better for business

05 Social Media: A Health Hazard?

The case to embrace going social

Creating a Lifeline to the New Digital User

Today, we’re focussed on getting to know our new target: she’s online, mobile, and connected to a large network of friends, information, and marketers who help her make decisions about...

Warehousing of HCV patients reaches new high

White Papers and Resources | December 19, 2013 | Inizio

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

White Papers and Resources | December 19, 2013 | Inizio

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Removing the Roadblocks to Effective Patient Treatment

White Papers and Resources | November 22, 2013 | Inizio

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...

Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

White Papers and Resources | November 22, 2013 | Inizio

Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...